Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection

被引：0
|
作者：
Lo, S. S.
Norton, J.
Mumby, P. B.
Smerage, J.
Kash, J.
Chew, H. K.
Hayes, D.
Epstein, A.
Albain, K. S.
机构：
[1] Loyola Univ, Maywood, IL 60153 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Edward Hosp, Naperville, IL USA
[4] Univ Calif Davis, Sacramento, CA 95817 USA
[5] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Relationship between Recurrence Score of 21-Gene Assay and Clinicopathological Factors of Breast Cancer
    Woolf, K.
    Wang, J.
    Hicks, D. G.
    Wang, X.
    Shciffhauer, L. M.
    Skinner, K.
    Tang, P.
    LABORATORY INVESTIGATION, 2010, 90 : 79A - 79A
  • [32] Recurrence Score of 21-Gene Assay Is Correlated with a Panel of Immunopathological Factors of Breast Cancer
    Subik, K.
    Delaney, A.
    Wang, J.
    Wang, X.
    Schiffhaner, L. M.
    Shayne, M.
    Huston, A.
    Skinner, K.
    Hicks, D. G.
    Tang, P.
    LABORATORY INVESTIGATION, 2010, 90 : 74A - 74A
  • [33] Use across Michigan of the 21-gene recurrence score (RS) assay in lymph node positive patients with breast cancer
    Henry, N. L.
    Ali, H.
    Braun, T.
    Munir, K.
    Silver, S. M.
    Griggs, J. J.
    Breslin, T. M.
    Gorski, D. H.
    CANCER RESEARCH, 2016, 76
  • [34] The Relationship between Recurrence Score of 21-Gene Assay and Clinicopathological Factors of Breast Cancer
    Woolf, K.
    Wang, J.
    Hicks, D. G.
    Wang, X.
    Schiffhauer, L. M.
    Skinner, K.
    Tang, P.
    MODERN PATHOLOGY, 2010, 23 : 79A - 79A
  • [35] Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer
    Zeng, Yufei
    Gao, Weiqi
    Lin, Lin
    Chen, Xiaosong
    Shen, Kunwei
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (05) : 843 - 849
  • [36] PONDx, A Prospective Multicenter French survey of the 21-Gene Assays: Impact on Treatment Selection in Lobular Breast Cancer Patients
    Furtos-Fanget, C.
    Conforti, R.
    Michaud, P.
    Darmon, J. C.
    Gozy, M.
    Belkacemi, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S156 - S156
  • [37] Recurrence Score of 21-Gene Assay Is Correlated with a Panel of Immunopathological Factors of Breast Cancer
    Subik, K.
    Delaney, A.
    Wang, J.
    Wang, X.
    Schiffhauer, L. M.
    Shayne, M.
    Huston, A.
    Skinner, K.
    Hicks, D. G.
    Tang, P.
    MODERN PATHOLOGY, 2010, 23 : 74A - 74A
  • [38] PONDx: a prospective multicenter French study of the 21-gene assays: impact on treatment selection in patients with high-risk breast cancer
    Gligorov, J.
    Bourgeois, H.
    Dohollou, N.
    Dewas, S.
    Wassermann, J.
    Tixier, L.
    Bourgeois, D.
    Genet, D.
    Coscas, Y.
    Khayat, D.
    BREAST, 2017, 32 : S61 - S61
  • [39] Impact of the 21-gene recurrence score assay on treatment decision in early breast cancer (EBC) patients with favourable prognostic factors
    Markopoulos, C.
    BREAST, 2011, 20 : S44 - S44
  • [40] A prospective multicenter study evaluating the impact of the 21-Gene Breast Recurrence Score® upon physician treatment decision and cost in lymph node-positive breast cancer patients in Quebec
    Hassan, Saima
    Younan, Rami
    Patocskai, Erica
    Provencher, Louise
    Poirier, Brigitte
    Sideris, Lucas
    Dube, Pierre
    Boileau, Jean-Francois
    Mihalcioiu, Catalin
    Robidoux, Andre
    CANCER RESEARCH, 2021, 81 (04)
12345